01-03-2019
peshkova / Shutterstock.com
The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate (SPC).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Genentech, Eli Lilly, English High Court, marketing authorisation, supplementary protection certificate, SPC, psoriasis, rheumatoid arthritis, Brexit
UK govt’s £20m fund for life sciences opens for applications
08-04-2021
Genentech to face revived Hemlibra claims
28-08-2020
Eli Lilly claims another victory in Taltz patent battle
18-02-2020
Former Genentech employee cuts plea deal with FBI in trade secrets case
16-01-2020
CJEU opinion on SPC referral is ‘overdue’, say lawyers
05-03-2019
